Atara biotherapeutics announces the completion of the acquisition of its cell therapy manufacturing facility & commencement of long-term strategic partnership with fujifilm

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced fujifilm diosynth biotechnologies, a subsidiary of fujifilm corporation (fujifilm), has completed the acquisition of atara's cell therapy manufacturing facility in thousand oaks, california for usd 100 million upfront and
ATRA Ratings Summary
ATRA Quant Ranking